Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A y Mice

American Journal of Hypertension

Volumn 24, Issue 2, 2011, Pages 169-174

  Iwai, Masaru ^a   Kanno, Harumi ^a   Inaba, Shinji ^a   Senba, Izumi ^a   Sone, Hisako ^a   Nakaoka, Hirotomo ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

blood pressure; diabetes; hypertension; insulin resistance; nifedipine; oxidative stress; white adipose tissue

Indexed keywords

ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID BINDING PROTEIN; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; NIFEDIPINE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSULIN BLOOD LEVEL; INSULIN TOLERANCE TEST; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RETROPERITONEUM; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

ADIPOCYTES; ADIPOGENESIS; ADIPONECTIN; ADIPOSE TISSUE, WHITE; ANIMALS; BLOOD GLUCOSE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY ACID-BINDING PROTEINS; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 4; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED STRAINS; NADPH OXIDASE; NIFEDIPINE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PPAR GAMMA; RECEPTORS, ANGIOTENSIN; SUPEROXIDE DISMUTASE; TIME FACTORS; WEIGHT LOSS;

EID: 78751618184     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.198     Document Type: Article

References (25)

1. Weidmann P, Böhlen L, de Courten M. Insulin resistance and hyperinsulinemia in hypertension. J Hypertens Suppl 1995; 13:S65-S72.
2. Shinozaki K, Ayajiki K, Nishio Y, Sugaya T, Kashiwagi A, Okamura T. Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension 2004; 43:255-262.
3. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46:821-826.
4. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20:579-586.
5. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008; 21:206-212.
6. Burnier M, Pruijm M, Wuerzner G. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol 2009; 5:981-987.
7. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
9. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15:2727-2729.
10. Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 2006; 319:1081-1087.
11. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, Rakugi H, Ogihara T, Horiuchi M. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43:263-269.
12. Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage. J Hypertens 2006; 24:2023-2031.
13. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005; 45:545-551.
14. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, Zaccaro D, Bergman RN, Savage PJ, Haffner SM. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension 2004; 43:1324-1331.
15. Yoshii T, Iwai M, Li Z, Chen R, Ide A, Fukunaga S, Oshita A, Mogi M, Higaki J, Horiuchi M. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 2006; 29:457-466.
16. Wu L, Iwai M, Li Z, Li JM, Mogi M, Horiuchi M. Nifedipine inhibited angiotensin II-induced monocyte chemoattractant protein 1 expression: involvement of inhibitor of nuclear factor κ B kinase and nuclear factor κ B-inducing kinase. J Hypertens 2006; 24:123-130.
17. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR)α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARα, PPARγ, and their combination. Diabetes 2005; 54:3358-3370.
18. Tsuchida A, Yamauchi T, Kadowaki T. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor γ, CREB-binding protein, and adiponectin. J Pharmacol Sci 2005; 97:164-170.
19. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 2009; 43:157-168.
20. Ishii N, Matsumura T, Kinoshita H, Fukuda K, Motoshima H, Senokuchi T, Nakao S, Tsutsumi A, Kim-Mitsuyama S, Kawada T, Takeya M, Miyamura N, Nishikawa T, Araki E. Nifedipine induces peroxisome proliferator-activated receptor-γ activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2010; 30:1598-1605.
21. Ohno T, Kobayashi N, Yoshida K, Fukushima H, Matsuoka H. Cardioprotective effect of benidipine on cardiac performance and remodeling in failing rat hearts. Am J Hypertens 2008; 21:224-230.
22. Passacquale G, Desideri G, Croce G, Murgo S, Mancarelli MM, Zazzeroni F, Alesse E, Ferri C. Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation. J Hypertens 2008; 26:737-746.
23. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010; 55:813-818.
24. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51:742-748.
25. Negro R, Hassan H. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. J Renin Angiotensin Aldosterone Syst 2006; 7:243-246. (Pubitemid 46380776)